IPCALAB:NSE-IPCA Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 918.50

Change

+5.60 (+0.61)%

Market Cap

INR 231.10B

Volume

0.13M

Avg Analyst Target

INR 1,140.00 (+24.12%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


IPCALAB Stock Forecast & Price:
Based on the IPCA Laboratories Limited stock forecasts from 6 analysts, the average analyst target price for IPCA Laboratories Limited is INR 1,140.00 over the next 12 months. IPCA Laboratories Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of IPCA Laboratories Limited is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, IPCA Laboratories Limited’s stock price was INR 918.50. IPCA Laboratories Limited’s stock price has changed by +0.67% over the past week, +6.66% over the past month and -8.85% over the last year.

About IPCA Laboratories Limited (IPCALAB:NSE)

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmint ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+0.15 (+0.02%)

INR1,994.80B 61.13 27.65
DIVISLAB:NSE Divi's Laboratories Limited

+2.00 (+0.05%)

INR958.40B 32.37 23.30
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-31.45 (-0.72%)

INR714.85B 30.40 15.87
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-12.80 (-0.44%)

INR493.58B 63.50 24.32
PEL:NSE Piramal Enterprises Limited

+7.60 (+0.45%)

INR400.11B 20.85 11.08
ALKEM:NSE Alkem Laboratories Limited

+20.20 (+0.67%)

INR358.31B 21.77 16.10
AUROPHARMA:NSE Aurobindo Pharma Limited

+6.80 (+1.30%)

INR304.98B 11.52 6.32
LUPIN:NSE Lupin Limited

N/A

INR283.50B 25.10 71.38
LAURUSLABS:NSE Laurus Labs Limited

+4.55 (+0.98%)

INR248.55B 30.06 19.05
AJANTPHARM:NSE Ajanta Pharma Limited

-24.85 (-1.97%)

INR159.98B 22.20 14.90

ETFs Containing IPCALAB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.22% 66% D 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.22% 66% D 47% F
Trailing 12 Months  
Capital Gain -9.93% 72% C- 44% F
Dividend Return 0.39% 39% F 24% F
Total Return -9.54% 72% C- 43% F
Trailing 5 Years  
Capital Gain 282.71% 91% A- 93% A
Dividend Return 4.38% 83% B 58% F
Total Return 287.08% 91% A- 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 42.36% 77% C+ 79% C+
Dividend Return 0.33% 35% F 27% F
Total Return 42.69% 75% C 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 34.29% 78% C+ 79% C+
Risk Adjusted Return 124.51% 98% A+ 99% A+
Market Capitalization 231.10B 88% B+ 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.14 37% F 38% F
Price/Book Ratio 4.17 28% F 25% F
Price / Cash Flow Ratio 27.00 34% F 24% F
EV/EBITDA 16.39 33% F 29% F
Management Effectiveness  
Return on Equity 17.30% 71% C- 70% C-
Return on Invested Capital 15.22% 69% D+ 77% C+
Return on Assets 9.82% 75% C 83% B
Debt to Equity Ratio 7.20% 60% D- 60% D-
Technical Ratios  
Dividend Yield 0.88% 50% F 46% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.12 96% A 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.